Skip to main content
Bentham Open Access logoLink to Bentham Open Access
. 2011 Mar;11(2):93–109. doi: 10.2174/156652411794859250

Practical Aspects of microRNA Target Prediction

TM Witkos 1, E Koscianska 1, WJ Krzyzosiak 1,*
PMCID: PMC3182075  PMID: 21342132

Abstract

microRNAs (miRNAs) are endogenous non-coding RNAs that control gene expression at the posttranscriptional level. These small regulatory molecules play a key role in the majority of biological processes and their expression is also tightly regulated. Both the deregulation of genes controlled by miRNAs and the altered miRNA expression have been linked to many disorders, including cancer, cardiovascular, metabolic and neurodegenerative diseases. Therefore, it is of particular interest to reliably predict potential miRNA targets which might be involved in these diseases. However, interactions between miRNAs and their targets are complex and very often there are numerous putative miRNA recognition sites in mRNAs. Many miRNA targets have been computationally predicted but only a limited number of these were experimentally validated. Although a variety of miRNA target prediction algorithms are available, results of their application are often inconsistent. Hence, finding a functional miRNA target is still a challenging task. In this review, currently available and frequently used computational tools for miRNA target prediction, i.e., PicTar, TargetScan, DIANA-microT, miRanda, rna22 and PITA are outlined and various practical aspects of miRNA target analysis are extensively discussed. Moreover, the performance of three algorithms (PicTar, TargetScan and DIANA-microT) is both demonstrated and evaluated by performing an in-depth analysis of miRNA interactions with mRNAs derived from genes triggering hereditary neurological disorders known as trinucleotide repeat expansion diseases (TREDs), such as Huntington’s disease (HD), a number of spinocerebellar ataxias (SCAs), and myotonic dystrophy type 1 (DM1).

Keywords: Bioinformatics, gene regulation, miRNA, miRNA-mRNA interaction, neurodegeneration, target prediction algorithm, target validation, trinucleotide repeat expansion disorders.

INTRODUCTION

microRNAs (miRNAs) are small non-coding RNAs about 22 nucleotides in length that play an important role in posttranscriptional regulation of target genes both in plant and animal cells. It is estimated that over half of mammalian protein coding-genes are regulated by miRNAs and most human mRNAs have binding sites for miRNAs [1, 2]. Until now 1048 human miRNAs have been annotated in miRNA registry (miRBase, Release 16) [3] and this number is steadily growing. miRNAs downregulate gene expression mostly by imperfect binding to complementary sites within transcript sequences and suppress their translation, stimulate their deadenylation and degradation or induce their cleavage [4, 5]. miRNAs originate from genome-encoded primary transcripts (pri-miRNAs) forming distinctive hairpin structures that are cleaved by the ribonuclease Drosha [6, 7] to ~60 nucleotide-long pre-miRNAs which are further trimmed by the ribonuclease Dicer [8, 9] to imperfect ~22-nt duplexes. One strand of the duplex is incorporated into RNA-induced silencing complex (RISC) [10, 11] and becomes a functional miRNA. miRNAs have been shown to be crucial for the majority of physiological processes; development, cell proliferation and cell death [12, 13]. Therefore, their deregulation has been associated with many diseases such as cancer, cardiovascular and neurodegenerative diseases or metabolic disorders [14-17]. Hence, miRNA expression analysis has a diagnostic value and normalizing miRNA levels is one of the promising therapeutic approaches [18-20].

Several types of miRNA target binding sites, differing in the position and localization of Watson-Crick pairings and mismatches, have been distinguished [21]. Plant miRNA target sites are located within open reading frames (ORFs) of target genes and nearly full complementarity is required between miRNAs and their target transcripts [22]. Therefore, a basic matching of plant miRNA and mRNA sequences serves as an efficient and accurate prediction method [23]. Unfortunately, this strategy could not be simply applied to the animal models since strict complementarity between the target site and the miRNA is a rare phenomenon [24]. Moreover, miRNAs are predominantly found in 3’ untranslated regions (3’ UTRs) of target genes and only sporadically in 5’UTRs or ORFs [25-27].

Effective prediction of miRNA-mRNA interactions in animal systems remains challenging due to the interaction complexity and a limited knowledge of rules governing these processes. Therefore, it is necessary to take advantage of the newest findings in miRNA biology and their targets prediction algorithms to find possible miRNA-mRNA interactions. Numerous target prediction algorithms exploiting different approaches have been recently developed, and many methods of experimental validation have been designed. In this review we summarize hitherto known facts on miRNA-mRNA interactions, describe functions and approaches of commonly used target predictions algorithms and methods for experimental validation. We also draw attention to practical aspects of computational miRNA target analysis and present our approach to miRNA target prediction using the example of genes causing trinucleotide repeat expansion diseases (TREDs).

miRNA-mRNA INTERACTIONS

Target sites for animal miRNAs are not evenly distributed within 3’UTR but they rather tend to group at both ends of 3’UTR [28]. It is typical of genes with short 3’UTRs to have target sites at 5’ part of 3’UTR [29]. Alternative transcripts with varied length of 3’UTRs could be regulated by different sets of miRNAs [30]. There is also an abundance of mRNAs having potential multiple sites for the same miRNA [31-33]. It was reported that multiple sites enhance the degree of downregulation [34] and many target prediction algorithms exploit this fact in their search and scoring. Two sites of the same or different miRNAs located closely to each other could act synergistically [33, 35]. Regions of strict complementarity, bulges and mismatches have been observed in almost all known miRNA-mRNA interactions in animals [21, 36]. Each of these duplexes has a region called the “seed”, a site located at 5’ part of miRNA (positions 2-7) which is characterized by a strict or almost strict Watson-Crick pairing between miRNA and its target site and shows the best conservation among the miRNA sequence [37]. It has to be pointed out that there is no single model that would depict all miRNA-mRNA interactions because of their relative heterogeneity. The classification of miRNA target sites is based on the complementarity within 5’ (the seed region) and 3’ part of miRNA (Fig. 1) and distinguishes three types of sites: 1) canonical, 2) 3’-supplementary and 3) 3’-compensatory sites [21].

Fig. (1). Types of miRNA-mRNA interactions.

Fig. (1). Types of miRNA-mRNA interactions.

Different classes of miRNA target sites are presented in a schematic way. Vertical dashes represent single Watson-Crick pairing. Nucleotides involved in binding have been arbitrarily defined to depict positions of required complementarity between miRNA and mRNA. Seed regions of miRNAs are marked by red color and the adenine at binding position 1 by green. Interactions between mRNA and the 3’ end of miRNA have not been shown because they are sequence-dependent and do not significantly contribute to the miRNA downregulation effect. In the case of 3’-suppelmentary and 3’-compensatory sites two regions of pairing (base pairs colored in blue) force middle mismatches to form a loop structure. Additionally, features of particular site types have been listed.

The majority of known targets called canonical sites have a complete paring within the seed region which determines the certainty of the interaction. There are three types of canonical sites [38]: the 7mer1A that has an adenine in position 1 at the 5’ end of miRNA, the 8mer having matched adenine in position 1 and an additional match in position 8 and the 7mer-m8 that has a match in position 8. Canonical sites account for the majority of validated conserved targets, 7mer sites are most abundant for highly conserved miRNAs [1] and the adenine opposite position 1 of miRNA improves the degree of gene silencing [39]. There are also known sites with shorter, 6-nt seed but they are thought to have a limited functionality. All of these groups can have an additional pairing within 3’ part of miRNA and corresponding nucleotides of the transcript (3’-supplementary sites) but it usually has a less profound effect on target recognition and its efficacy [33]. At least 3-4 nucleotides consecutively paired in positions 13-16 of miRNA are usually required to enhance the effectiveness of miRNA-mRNA interaction which facilitates target prediction. There is also a possibility of a mismatch in the seed which is compensated by additional extended pairing in 3’ part of miRNA (3’-compensatory sites).

The complexity of miRNA-mRNA interactions is one of the main reasons why algorithms based on a miRNA-mRNA sequence matching only are insufficient and additional parameters such as orthologous sequences alignment, UTR context or free energy of complexes have to be taken into account. 3’UTR orthologous sequence analysis is a basic method of making the miRNA target prediction more efficient [40] and it is restricted to a comparison of conservative sequences in human transcriptome to relatively evolutionally distant species such as the mouse, the dog or the fish. It is based on the assumption that sites, as targets for miRNA regulation, have been kept unchanged because of evolutionary pressure [1, 41]. It has been well proven that some miRNA families are highly conserved among closely related species, have many conserved targets and family members differ in the 3’ region that enables distinction of sensitivity to transcript targets [38]. Friedman et al. [1] suggested that most mammalian targets retain sites for conserved miRNAs. The use of an approach based on sequence conservation seems to be entirely justifiable for an analysis of seed regions [38, 42]. However, this strategy should be applied with caution because even conserved 3’UTRs have a large number of non-conserved targets. This is one of the main reasons why algorithms based on orthologous sequence alignment generate a number of false negative results. There is also an abundance of miRNAs that are not conserved and different approach is needed for prediction of their targets. In this case it is extremely important to implement other search parameters. It is known that simple base pairing is insufficient for miRNA target prediction [43] and the secondary structure of miRNA/target duplexes is a factor that should be taken into consideration [44, 45]. Many existing algorithms based on conservation analyses include the sequence-based binding energy of miRNA-target duplex calculations into a final score. Kertesz et al. [46] conducted a more in-depth analysis which centered on the site accessibility for miRNA downregulation efficacy. It turned out that upstream and downstream flank regions of miRNA binding sites tend to have weak base-pairing to reduce the energy cost of unpairing bases in order to make the site more accessible for RISC. This observation is in agreement with the fact that target flanking regions have high local AU content [33]. It was proposed that some miRNAs downregulate moderately targeted mRNAs and they are engaged in tuning gene-expression levels [47]. Moreover, certain target sites may act as competitive inhibitors of miRNA activity since the effect of miRNA regulation on them is very mild [48]. These sites will retain their conservation since they have a biological function as miRNA sequestration regulators.

miRNA TARGET PREDICTION ALGORITHMS

Many different algorithms have been developed for prediction of miRNA-mRNA interactions. The rules for targeting transcripts by miRNAs have not been fully examined yet and are based mainly on experimentally validated miRNA-mRNA interactions [49, 50] that are only a slice of possibly existing in vivo. This situation led to the development of a variety of approaches to miRNA target prediction. The available algorithms have been extensively discussed by others [51-54]. Moreover, they were recently reviewed by Yue et al. [55] with the focus on their bioinformatical, mathematical and statistical aspects. The available algorithms can be classified into two categories established on the basis of the use or non-use of conservation comparison, a feature that influence greatly an outcome list of targets by narrowing the results [1, 33]. The algorithms based on conservation criteria are for example the following: miRanda [56], PicTar [42, 57], TargetScan [38], DIANA-microT [36]; while PITA [46] and rna22 [58] belong to the algorithms using other parameters, such as free energy of binding or secondary structures of 3’UTRs that can promote or prevent miRNA binding. Since all these algorithms were successfully used to predict miRNA targets in mammals we describe them in more detail below. Additionally, to facilitate the assessment of these algorithms, we summarize their performance and characteristic features (Table 1).

Table 1.

Features, Experimental Evaluation Results and Assessment of Commonly Used Algorithms in miRNA Target Prediction

Target prediction algorithm Features Experimental evaluation results Assessment Reference
Parameters contributing to the final score Cross-species conservation Sethupathy et al. 2006 Baek et al. 2008 Alexiou et al. 2009 Advantages Disadvantages
sensitivity1 log2-fold change2 precision3 sensitivity4
miRanda complementarity and free energy binding conservation filter is used 49% 0.14 29% 20% - beneficial for prediction sites with imperfect binding within seed region - low precision, too many false positives [56]
TargetScan seed match, 3’ complementarity local AU content and position contribution5 given scoring for each result 21% 0.326 51% 12% - many parameters included in target scoring
- final score correlates with protein downregulation
- sites with poor seed pairing are omitted [38]
TargetScanS seed match type only conservative sites are considered 48% 49% 8% - simple tool for search of conserved sites with stringent seed pairing - underestimate miRNAs with multiple target sites [38]
PicTar binding energy, complementarity and conservation required pairing at conserved positions 48% 0.26 49% 10% - miRNAs with multiple alignments are favored - does not predict non-conservative sites [42, 57]
DIANA-microT free energy binding and complementarity dataset of conserved UTRs among human and mouse is used 10% 48% 12% - SNR ratio and probability given for each target site
- possibility of using own miRNA sequence as an input
- some miRNAs with multiple target sites may be omitted [36]
PITA target site accessibility energy user-defined
cut-off level
0.046 26% 6% - the secondary structure of 3’UTR is considered for miRNA interaction - low efficiency compared to other algorithms [46]
Rna22 pattern recognition and folding energy not included 0.09 24% 6% - allows to identify sites targeted by yet-undiscovered miRNAs - low efficiency compared to other algorithms [58]
1

percentage of experimentally supported miRNA-target gene interactions predicted (used TarBase records for which a direct miRNA effect was examined).

2

average protein depression of genes predicted by the algorithm to be miR-223 targets.

3

proportion of correctly predicted target miRNAs to total predicted miRNA-mRNA interactions (data obtained from proteomic analyses carried out by Selbach et al.).

4

proportion of correctly predicted target miRNAs to total correct miRNA-mRNA interactions (data obtained from proteomic analyses carried out by Selbach et al.).

5

position contribution parameter promotes sites close to the 3’UTR ends.

6

the final scoring correlates with the level of protein downregulation.

miRanda

The miRanda algorithm [56] is based on a comparison of miRNAs complementarity to 3’UTR regions. The binding energy of the duplex structure, evolutionary conservation of the whole target site and its position within 3’UTR are calculated and account for a final result which is a weighted sum of match and mismatch scores for base pairs and gap penalties. There is one wobble pairing allowed in the seed region that is compensated by matches in the 3’ end of miRNA. The usage of this strategy incorporates different nature of miRNA-mRNA interactions (Fig. 1). miRNAs with multiple binding sites within 3’UTR are promoted, which contributes to the increase in specificity but it underestimates miRNAs with a single but perfect base pairing. It takes into account the evolutionary relationships of interactions more globally focusing on the conservation of miRNAs, relevant parts of mRNA sequences and the presence of a homologous miRNA-binding site on the mRNA [59].

TargetScan and TargetScanS

These algorithms [38] use different approach to the prediction of interactions of miRNAs with mRNAs. Firstly, the search is narrowed to the sites that have full complementarity in the miRNA seed region that is defined as 6-nt long (nucleotides 2-7) and then they are extended to 21-23 nucleotide-long fragments representing true interactions. Results are classified within three groups on the basis of length of exact matching and an occurrence of adenine at the first position of mRNA target site which seems to be evolutionally conserved [39] and may act as a recognizing anchor for RISC. Several parameters determined in previous signal-to-noise analyses on an experimentally validated dataset contribute to the outcome score such as the type of seed matching, pairing contribution outside the seed region, AU content 30 nt upstream and downstream of predicted site and the distance to the nearest end of the annotated UTR of the target gene [33]. The conservation of seed regions among orthologous 3’UTRs within miRNA binding regions has a fundamental importance for an outcome score [1]. Less conservative miRNA-mRNAs interactions with wobble pairings and bulges, especially within 5’ region of miRNA, are also predicted in the newest versions.

TargetScanS [38] is an alternative, simplified version of TargetScan which predicts targets having a conserved 6-nt seed match flanked by either a 7-nt match or 6-nt with A on the 3’ terminus with no consideration of free energy values.

PicTar

PicTar [42, 57] searches for nearly but not fully complementary regions of conservative 3’UTRs and then calculates the free energy of created duplexes. Each result is scored using Hidden-Markov Model (HMM – a simple example of dynamic Bayesian network), miRNAs with multiple alignments are favored. It was the first method that considered a parallel expression on the cellular level or an action in a common biological pathways of a miRNA and transcript. PicTar uses sequence alignment to eight vertebrate species to eliminate false positive results and it scores the candidate genes of each species separately to create a combined score for a gene. It is necessary for the mRNA to have recurring nucleobases at overlapping positions among species paired.

DIANA-microT

This algorithm [36] uses a 38nt-long frame that is moved along 3’UTR. The minimum energy of potential miRNA binding, that allows mismatches, is measured after every shift and compares with the energy of 100 per cent complementary sequence bound to the 3’UTR region. DIANA-microT searches for sites with canonical central bulge and it requires 7, 8 or 9 nt–long complementarity in 5’ region of miRNA. 6 nt-long matches within seed region or with one wobble pairing are also considered while enhanced by additional base pairing in 3’ region of miRNA [60]. Because of exploiting experimental deduction of rules governing miRNA-mRNA site by their mutation it is constructed for single site prediction. DIANA-mciroT use conservative alignment for scoring but also considers non-conservative sites. It gives unique signal-to-noise ratio (SNR) which is a ratio between a total of predicted targets by single miRNA in searched 3’UTR and a total of predicted targets by artificial miRNA with randomized sequence in searched 3’UTR. It also provides users with a percentage probability of existence for each result depending on its pairing and conservation profile.

PITA

PITA [46] offers a brand new view on the miRNA target prediction. It focuses on the target accessibility that is strictly connected to the secondary structure of the transcript. The main assumption is based on the fact that the mRNA structure plays a role in target recognition by thermodynamically promoting or disfavoring the interaction. PITA first predicts targets using complementarity analysis within seed regions (single mismatch or G:U wobble pairing can be allowed) and then compares the free energy gained from the formation of the miRNA-target duplex and the energetic cost of unpairing the target to make it accessible to the miRNA.

Rna22

Rna22 [58] is a target prediction algorithm that is based on a search for patterns that are statistically significant miRNA motifs created after a sequence analysis of known mature miRNAs. It first searches for reverse complement sites of patterns within mRNA of interest and determines sites with many patterns aligned (so called ‘hot spots’). The next step is identification of miRNAs that are likely to bind to these sites. This approach also allows to identify sites targeted by yet-undiscovered miRNAs. The minimum number of base-pairs between miRNA and mRNA, the maximum number of unpaired bases and the free energy cutoff are user-defined parameters. Rna22 does not exploit cross-species conservation alignment for final scoring.

PRACTICAL ASPECTS OF miRNA TARGET PREDICTION ALGORITHMS

Since the appearance of target prediction algorithms there has been a need to evaluate their precision and authenticity of outcome scores in order to estimate their effectiveness and select the best ones. Target prediction programs are a type of binary classification tests addressing the question of whether there is an interaction between miRNA and given target transcript or not. There are two statistical parameters that could be used to characterize their performance, namely sensitivity, a percentage of correctly predicted targets out of total correct ones, and specificity, a percentage of correctly predicted among overall predicted ones. These parameters are strictly connected with the false positive and false negative rates that, respectively, describe a number of targets that were experimentally rejected as untrue and targets that exist in vivo but are not predicted computationally. The choice of a program or programs for the analysis should take these two measures into account. In general, the emphasis is put more on sensitivity in the search of all potential targets for specific miRNA and on specificity in the examination of miRNAs regulating a single gene.

Comparison of miRNA Target Prediction Algorithms

The first study of target prediction algorithms performance was carried out by Sethupathy et al. in 2006 [61]. The specificity and sensitivity were calculated using a set of experimentally validated mammalian targets from TarBase [49]. TargetScanS, PicTar and miRanda used alone or as a union (targets indicated by at least one of these algorithms) made the best tradeoff between sensitivity and specificity while TargetScan and DIANA-microT did not succeed. Also, only the intersection of TargetScanS and PicTar (interactions predicted by both programs) achieved good results which could be explained by exploiting similar strategy for miRNA target prediction based on evolutionary conservation of binding sites and strict complementarity within seed regions. The method of examination proposed by Sethupathy, however, might lead to wrong conclusions. The group of experimentally validated targets was not large and, more importantly, it consisted of only such interactions that had been discovered with the usage of the predetermined set of rules for miRNA target prediction. Because of still not having defined all possible types of miRNA-mRNA interaction, the analyzed group could not be regarded as representative.

High throughput methods provided information about the miRNA effects at the proteome level. The whole context of miRNA regulation was analyzed and therefore miRNA target prediction algorithms were compared more precisely. Baek et al. in 2008 [62] applied a quantitative-mass-spectrometry-based approach using SILAC (stable isotope labeling with amino acids in cell culture) to study the influence of miR-223 on the protein output in mouse neutrophils. The comparison between in vivo results and predictions in silico revealed that TargetScan and PicTar seemed to be the best ones and moreover, only TargetScan total context score, that is assigned to each result, correlated with protein downregulation. Algorithms not using evolutionary analysis such as PITA should be rather used for non-conserved targets only and still need an improvement. Analogous research was carried out by Alexiou et al. in 2009 [63]. They used data obtained inter alia from Selbach et al. experiments [64] that consisted in employing a modified SILAC method (pulse-labeling with two different heavy isotopes) combined with mass-spectroscopy analysis to observe changes in protein production after overexpression of 5 miRNAs (miR-1, miR-16, miR-30a, miR-155 and let-7b) in HeLa cells. The results showed that five programs (TargetScan, TargetScanS, PicTar, DIANA-microT and EIMMO [29]) had a specificity of around fifty per cent and six to twelve per cent of sensitivity which correlates with other reports [65]. Furthermore, they conducted similar analysis for all unions and intersections of miRNA target prediction algorithms. It can be concluded that a target predicted by more than one program is more likely to be true than other targets, although such an intuitive tendency may be misleading in many cases. The combinations of algorithms may result in the increase of the sensitivity at the cost of specificity.

In sum, there is no universal miRNA target prediction algorithm that can be used routinely and efficiently for every 3’UTR sequence since not all rules of mRNA-miRNA interactions have been discovered yet. Therefore, instead of having a clear result of computational analysis specifying whether there is a functional binding site or not, target prediction programs give point scores and percentages that only assess the possibility of interaction. This is a reason why researches from other fields of biomedical sciences are often lost in the abundance of available information and variety of miRNA target prediction algorithms.

Practical Insight into miRNA Target Prediction

To meet the need of a guidance in miRNA target prediction, the information about distinctive features of commonly used algorithms and their performance, advantages and drawbacks has been gathered (Table 1) and a flow chart showing the stages of the miRNA target prediction has been shown (Fig. 2). Table 1 presents the main parameters that are considered by programs for final scoring and also provides information about the conservation, which is the main feature distinguishing miRNA target prediction algorithms. Some of programs use the cross-species alignment as an indispensable factor to filter out false negatives (e.g., PicTar) or as a user-defined parameter to reduce the number of putative target sites (PITA), while other algorithms do not exploit this feature for final scoring (rna22). In many cases, the basic concept employed by algorithms in search of miRNA-mRNA predetermines the outcome advantages and weak points of used strategies. For instance, miRanda allows a wobble pairing within the seed region which adds 3’ compensatory sites to the list of predicted targets. However, at the same time, the allowance of wobble pairing lowers the algorithm precision. DIANA-microT examines each target site independently, providing additional parameters such as SNR and the probability of being a true site. Therefore DIANA-microT does not favor miRNAs with multiple target sites. PITA and rna22 are examples of algorithms focusing on novel features of miRNA-mRNA interaction; target site accessibility and pattern recognition, respectively. Their use broaden the list of potential miRNA target sites but these sites are predicted with low efficiency.

Fig. (2). The flow chart of steps for efficient miRNA target prediction.

Fig. (2). The flow chart of steps for efficient miRNA target prediction.

Details discussed in the main text.

The most suitable approach for miRNA target prediction seems to be dependent on the nature of planned experiments. Basic scientists want to perform comprehensive analysis to discover all true interactions while clinically-orientated researchers may be satisfied with the strongest interactions that could be employed in gene therapies. In Fig. (2) we present a schematic procedure which we believe will help to choose the appropriate strategy for computational analysis of miRNA-mRNA interactions. The first step is to use one of the programs that consider site conservation (PicTar, TargetScan or DIANA-microT) because they are characterized by high precision and sensitivity. As it was mentioned before, the combined use of them as an intersection or a union is less effective in most cases and therefore this procedure should not be used. These algorithms cannot be used for newly evolved genes that do not have their orthologs in distantly related species. The next step is to add targets indicated by programs exploiting other parameters for final scoring (e.g. PITA, rna22). This action should be treated as optional and it is encouraged to follow especially if previous steps give few putative miRNA-mRNA interactions. After selection of predicted miRNAs regulating the gene of interest, the expression profile of miRNAs and the gene should be compared to detect the overlaps and/or inverse correlations. miRGator, a tool for an integration of miRNA and mRNA expression data have been created [66]. It is a crucial step for assessing the putative physiological regulation of gene by miRNAs, especially when tissue-specific expression of miRNA may be linked to the disease of interest. Finally, close attention should be paid to putative target sites that are located in the immediate vicinity. Both the genome-wide analysis [33] and the experimental data [35] demonstrated that sites located close to each other often act synergistically. Although this feature is still not included in miRNA target prediction algorithms, it may play an important role in the mechanism of miRNA-mediated gene regulation.

EXPERIMENTAL VALIDATION OF PREDICTED TARGET SITES

Once miRNA has bound to its binding site within 3’UTR of the targeted transcript the following biological effects may be exerted: translational arrest effecting in protein level decrease, deadenylation of the transcript and/or its degradation resulting in both mRNA and protein levels reduction [4, 5]. The most straightforward method for verification of miRNA function is a transfection of cells with miRNA mimetics or miRNA inhibitors, followed by quantitative analyses of target mRNA and protein levels [67, 68]. miRNA mimetics imitating endogenous miRNAs may be delivered either in the form of synthetic siRNA-like duplexes or miRNA-encoding vectors (recently reviewed in [69]). Specific miRNA inhibitors commonly used to silence miRNA function are complementary oligoribonucleotides, usually modified, such as 2’-O-methyl-modified oligoribonucleotides [70], LNAs (locked nucleic acids) [71] and antagomirs (cholesterol-conjugated single-stranded RNAs) [72], or vector-based transcripts called “miRNA sponges”, containing multiple miRNA binding sites that absorb miRNAs and prevent binding their targets [73, 74]. To confirm direct interactions between miRNAs and mRNAs comprehensive analyses should be performed. Several methods for experimental verification of predicted miRNA-mRNA interactions are currently being used and percentage shares of targets validated by the use of a particular method are presented in Fig. (3). The most commonly used methods, i.e., reporter assays, microarrays and proteome analyses are detailed below. Experimentally validated miRNA-mRNA interactions have been gathered in various databases, such as TarBase [50], MiRecords [75], Ago [76] and miRNAMAP [77].

Fig. (3). The pie chart showing percentage shares of methods used successfully to validate experimentally miRNA targets.

Fig. (3). The pie chart showing percentage shares of methods used successfully to validate experimentally miRNA targets.

The numbers show the percentage shares of targets validated by the use of a particular method. Data were obtained from the latest release of Tarbase v 5.0, June 2008 [50].

Gene Reporter Assays

The very first approach exploited in the field of experimental validation of putative miRNA-mRNA interactions was the use of reporter assays, usually luciferase reporter assays, because miRNA activity on such reporter genes can be easily measured [42, 58]. This method is based on cloning 3’UTRs of genes of interest or 3’UTR segments containing miRNA binding site(s) into expression vectors bearing a reporter gene. As a negative control, constructs carrying 3’UTRs with mutated target sites that unable miRNAs binding are also used [36, 40, 78-82]. Transient transfection of cells with reporter constructs followed by measurement of the reporter activity enables validation of predicted miRNA-mRNA interactions. Cells not expressing a miRNA of interest may be co-transfected with the reporter construct and either a miRNA mimetic or a miRNA-encoding vector. This method is frequently extended and the miRNA-mRNA interaction is further confirmed by a transfection with miRNA inhibitors. The reporter assay still serves as an efficient and routinely used strategy for the verification of individual miRNA-mRNA interactions [83] (Fig. 3). Simplicity of the method is its main advantage, while the fact that it does not allow a high-throughput identification of miRNA targets is an important drawback.

Microarray Analysis

An increasingly popular and high-throughput method used in the experimental validation of miRNA-mRNA interactions is microarray analysis [65, 84] which takes advantage of the fact that one of the direct effects of miRNA binding is a simultaneous reduction in targeted transcripts’ levels [5, 62]. Such an analysis consists in the comparison of cell transcriptomes after miRNA overexpression or knockdown with reference to the transcriptome of untreated cells. The significant advantage of this method ids the fact that it enables performing a large-scale analysis. However, not all miRNA-mRNA interactions may be discovered by this method since miRNAs can downregulate genes by lowering protein expression levels with an undetected change in transcript levels [5]. Moreover, the transcriptomes vary between different tissues and highly depend on the cell physiology. Therefore, a strategy involving multiple set of microarrays was proposed to overcome these problems and ensure reliability of the method [85].

Proteome Analysis

Another high-throughput method successfully used in validation of miRNA target sites is the proteome analysis [62, 64]. Similarly to microarrays, the proteomics approach is based on measuring the change of protein level in response to miRNA introduction. This method employs stable isotope labeling with amino acids in cell culture (SILAC) followed by a quantitative-mass-spectrometry [62, 86]. Later, this technique was modified by conducting pulse labeling with two different heavy isotopes [64]. The proteome analysis is considered to be more proper to detect functional miRNA-mRNA interactions than microarrays but still both methods share common limitations, such as high dependency of trancriptome and proteome on cell physiology. Moreover, certain changes detected in protein levels may result from an indirect miRNA regulation instead of a direct effect of miRNAs binding to the targeted transcripts which is also a disadvantageous feature of the method.

Immunoprecipitation and Other Methods

Apart from the strategies mentioned above, other methods for experimental validation of miRNA-mRNA interactions have been introduced and successfully used (recently reviewed in [87]). AGO proteins of RISC can bind both miRNAs and mRNAs and this feature was exploited in co-immunoprecipitation assays [88, 89]. Used collectively with deep sequencing, AGO immunoprecipitation allowed validating of miRNA-mRNA interactions in a genome-wide manner. HITS-CLIP, namely high-throughput sequencing of RNAs isolated by crosslinking immunoprecipitation, was used to directly identify AGO-bound miRNAs and their target mRNAs in the mouse brain [90]. Such an approach complemented the bioinformatic way of the miRNA target identification and reduced the number of false-positive predictions. More recently, CLIP method was modified in respect of an ultraviolet irradiation used to covalently crosslink RNA-protein complexes within cells. The improved CLIP, termed PAR-CLIP (Photo-activatable-Ribonucleoside-Enhanced Crosslinking and Immunoprecipitation) was used by Hafner et al. [91] to analyze miRNPs (miRNA-RNA-protein) complexes in HEK293 cells. Despite being regarded as a very modern and elegant way to perform large-scale analyses, CLIP methods have some weaknesses. Not only are they technically challenging and expensive but frequently encounter problems with distinguishing between direct and indirect miRNA-mRNA interactions.

Furthermore, methods based on different approaches were also successfully implemented for the verification of miRNA-mRNA interactions. Davis et al. [92] conducted RNA-ligase-mediated (RLM) 5’ RACE experiments to verify miRNA-target interactions, and Li et al. [93] proposed that high cytoplasmic-to-nucleic ratio of mRNA expression may indicate genes that are likely to be controlled by miRNAs. In the latter report it was suggested that a measurement of the transcript level by a microarray or fluorescent real time PCR (qPCR) preceded by a computational analysis can be performed to create a list of potential targets [93].

Evaluation of miRNA Target Validation Methods

Commonly used methods for experimental validation have their own assumptions, strengths and weaknesses (reviewed in [94]). The most promising techniques are those which may be converted to a multiplex format, however they are not fully satisfying in terms of their sensitivity. On the other hand, more sensitive methods (e.g., reporter assays) cannot be used in large-scale analyses. Certain targets validated by reporter gene assays may be also false negatives as an effect of RISC saturation due to miRNA overexpression. Furthermore, inhibitors designed to exclusively repress the function of the specific miRNA (frequently used in all validation methods) may not be selective enough since many miRNAs belong to miRNA families with common seed regions and such inhibitors could trigger non-specific repression in many cases. Taken together, there are many pitfalls associated with miRNA target validation. All validation methods, including their advantages and drawbacks as well as future perspectives of miRNA target identification and miRNA-mRNA interaction analyses, have been extensively discussed elsewhere [54, 87, 94-96].

PREDICTION OF miRNA TARGETS IN TREDs

Many studies showed that miRNAs play a crucial role in the development and functional regulation of nervous system and deregulation of miRNAs was postulated and proved in various neurological disorders [97-100]. There have been published several reviews summarizing our current knowledge of neurodegeneration and its connections with miRNA regulation [101-105] but have been rather focused on neurodegenerative diseases such as Alzheimer’s and Parkinson’s. In this section we have summarized current knowledge about experimentally proven associations between miRNAs and TREDs (Table 2). Moreover, we provide a detailed analysis and show the practical side of miRNA target prediction on the example of miRNA interactions with mRNAs derived from genes triggering the pathogenesis of trinucleotide repeat expansion diseases (TREDs).

Table 2.

The Summary of Current Examinations of Links Between miRNA Regulation and TREDs

Disease miRNA change/regulation miRNA target prediction algorithms Methods used for experimental validation Experimental models References
Spinocerebellar ataxia type 1 (SCA1) miR-19, -101 and -130a downregulate ATXN1 gene PicTar was used to computationally predict miRNAs targeting ATXN1 transcript. Eight most likely miRNAs were chosen for experimental validation transfection with miRNA duplexes and their specific inhibitors followed by western blot analysis and RT-PCR MCF7, HEK293T, NIH3T3 and HeLa cell lines [111]
luciferase reporter assays with vectors carrying 3’UTR fragments or mutated target sites HeLa cell line
miRNA detection by northern blot analysis and in situ hybridization of mouse RNAs derived from cerebellum C57/B6 WT mouse
cell death assays with mutant ATXN1deprived of target sites HEK293T cell line
Spinocerebellar ataxia type 3 (SCA3) and possibly other polyQ disorders ban, a dma-miRNA, modulates polyQ-toxicity phenotype comparison analysis (mutants) D. melanogaster [118, 119]
cell death assays D. melanogaster cell line with ban overexpression
Dicer downregulation flies and human cell lines
Dentatorubral pallidoluysian atrophy (DRPLA) dma-miR-8 downregulates
D. melanogaster atrophin gene
phenotype comparison analysis (mutants) D. melanogaster [129]
mutant expression profiling microarray analysis fruit fly pupae
real-time RT-PCR with intron specific primers fruit fly pupae
luciferase reporter assay with vectors containing 3’UTR with mutated target sites fruit fly pupae and S2 cell line
in vivo studies of miR-8/atrophin functionality (death assays of mutants with atrophin and/or miR-8 underexpression, immmunocytochemistry for apoptotic cell detection) D. melanogaster, fruit fly embryos
Huntington’s Disease (HD) downregulation of miR-9, -9*, -29b, -124 and upregulation of miR-132 associates with HD quantitative real-time PCR (qPCR) using TaqMan miRNA assays human brain post mortem samples of the Brodmann’s area 4 (BA4) cortex [130]
co-transfection of miRNA precursors and REST/CoREST 3’UTRs with luciferase assay followed by western blot analysis HEK293 cell line
Huntington’s Disease (HD) downregulation of miR-132 and upregulation of miR-29a and -330 associate with HD infection with adenovirus expressing a dominant-negative REST construct followed by RT PCR cell lines of wt and mutant Hdh knock-in embryonic mice [131, 132]
qPCR using pre-miRNA stem loop primers R6/2 mouse (and human) post mortem samples of the cortex (BA4 cortex)
Huntington’s Disease (HD) downregulation of 15 miRNAs1 and upregulation of 192 and miRNA editing alterations associate with HD microPred pipeline for novel miRNAs prediction [133], TargetScan for prediction of genes regulated by altered miRNAs massively parallel sequencing of small non-coding RNAs (ncRNAs) followed by TaqMan microRNA assays human brain post mortem samples of the frontal cortex (FC) and the striatum (ST) [127]
Huntington’s Disease (HD) downregulation of 15 miRNAs3 and upregulation of 94 associates with HD miRNAMap 2.0 resource [77] (miRanda, TargetScan, RNAHybrid) was used for prediction of genes regulated by altered miRNAs qPCR using stem loop primers STHdhQ111/HdhQ111 cells - cell lines of wt and mutant Hdh knock in embryonic mice [115]
Spinocerebellar ataxia type 17 (SCA17) miR-146a downregulates TBP gene luciferase reporter assay with vectors containing exogenous TBP 3’UTR with western blot analysis
co-transfection of miRNA precursors and TBP 3’UTR followed by northern blot analysis
Myotonic dystrophy type 1 (DM1) overexpression of miR-206 associates with DM1 qPCR using TaqMan microRNA assays
northern and western blot analysis
in situ hybridization of miR-206 using locked nucleic acid probes (LNA)
human muscle samples of vastus lateralis [134]
Fragile X syndrome (FXS) dFmrp associates with RISC and endogenous miRNAs transcfection with vectors containing dFmrp
co-immunoprecipitation with RISC proteins and miRNAs, norther and western blot analysis
S2 cell line [123]
Fragile X syndrome (FXS) dFmrp is required for processing of miR-124a in situ hybridization of dma-miR-124a D. melanogaster embryos [125]
immunoprecipitation with miR-124a, norther and western blot analysis qPCR using stem loop primers transgenic fruit fly pupae
Fragile X syndrome (FXS) miR-19b, -302b* and -323-3p downregulate FMR1 gene intersection of computationally predicted targets by miRbase [3], miRanda and miRDB was used for validation luciferase reporter assays with vectors containing native 3’UTR or with mutated target sites combined with co-transfection of GFP-tagged plasmids expressing pre-miRNAs HEK293 cell line [116]
1

miR-95, -124, -128, -127-3p, -139-3p, -181d, -221, -222, -382, -383, -409-5p, -432 , -433, -485-3p and -485-5p.

2

miR-15b, -16, -17, -19b, -20a, -27b, -33b, -92a, -100, -106b, -148b, -151-5p, -193b, -219-2-3p, -219-5p, -363, -451, -486-5p and -887.

3

miR-9, -9*, -100, -125b, -135a, -135b,-138, -146a, -150, -181c, -190, -218, -221, -222 and -338-3p.

4

miR-145, -199-5p, -199-3p, -148a, -127-3p, -200a, -205, -214 and -335-5p.

Brief Characteristics of TREDs and Mechanisms of Pathogenesis

TREDs comprise mostly neurodegenerative disorders, such as Huntington’s disease (HD) and a number of spinocerebellar ataxias (SCAs), and neuromuscular disorders, such as myotonic dystrophy type 1 (DM1). The underlying cause of TREDs is an expansion, to an abnormal length, of trinucleotide repeats (TNRs), CAG, CTG, CGG and GAA, that occur both in coding and non-coding regions of human genes [106-108]. The same type of mutation is a characteristic of all genes triggering TREDs but these genes do not perform similar functions. However, this group of disorders could be divided into categories with regard to the localization of expanded TNRs within genes and the mechanism of pathogenesis. The expansion of TNRs could result in either the loss-of-function mechanism which consists in protein function impairment, i.e., reduction or absence of protein production, or the gain-of-function resulting in an altered function of the mutant protein or toxicity of the mutant transcript. The mechanism of pathogenesis also determines the choice of miRNA features that should be considered in the employment for therapy.

microRNAs as Therapeutic Agents

Polyglutamine (Poly-Q) diseases, a group of TREDs such as HD and several SCAs where the translated CAG repeats expand, are predominantly caused by the toxic polyQ-expanded protein [106-108] with possible contribution from mutant transcript [109, 110]. As yet no conventional therapy could be applied to treat patients with these diseases and employment of miRNA machinery and function seems to be one of the promising therapeutic approaches. Pioneering research in this area was conducted by Lee et al. [111]. They showed that the level of ATXN1, the protein being a product of ATXN1 gene, is modulated by miRNAs and the inhibition of miRNAs targeting ATXN1 transcript enhanced cell toxicity. In the case of polyQ-diseases, miRNAs could reduce levels of both the affected protein and mutant transcripts. Although miRNAs would not discriminate between the mutant and normal transcripts, tighter regulation of the protein level itself was demonstrated to have therapeutic efficacy in HD [112]. Another possibility to consider is to construct artificial miRNAs targeting new sites in 3’UTRs. Taking advantage of miRNAs as therapeutic agents may be more beneficial in some circumstances than the use of siRNAs since miRNAs could offer better specificity and lower toxicity [20]. It appears to be prudent to deliver to the affected tissue lower doses of different specific miRNAs instead of a high dose of single miRNA regulating the gene of interest, since the effect of lower doses should be additive. This approach may also diminish the undesired effect of decreasing the off-target genes’ expression because the most downregulated would be genes having target sites for all introduced miRNAs. An interesting approach to explore would be a use of miRNAs that regulate the gene of interest but are not expressed in the affected tissues. This strategy could provide higher specificity since a smaller number of existing transcripts may have target sites for the miRNA not expressed normally in this tissue.

DM1 is caused by the accumulation of a toxic transcript in the nucleus [113] which apparently limits the use of miRNAs in the therapy since miRNA regulation takes place predominantly in the cytoplasm. The transcript toxicity would narrow down miRNAs to those that act as gene regulators both on the protein and the transcript levels but this does not seem to be a serious limitation as it was proved recently that majority of miRNAs decrease target mRNA levels [5]. Furthermore, it was shown that miRNAs having nuclear localization signal were imported to the nucleus and downregulated nuclear transcripts [114]. It may be beneficial to employ this knowledge in constructing artificial miRNAs for targeting the DMPK transcript retained in the nucleus. The possibility of targeting genes in an allele-specific manner in the disease caused by expanded CUG repeats such as DM1 was also considered as miRNAs with CAG repeats in their seed regions may potentially regulate mutated alleles more tightly. It was proposed in Hon and Zhang [28] that the length of CUG repeats could correlate with the miRNA repression in the case of 3’UTR of DMPK. Six miRNAs having CAG repeats within their seed regions were identified and it was indicated by in silico studies that they could regulate the expression of DMPK by multiple targeting the region of CTG repeats in its 3’UTR. Further analysis and experimental validation of this proposition is needed.

Analysis of miRNA-mRNA Interactions on the Example of TREDs’ Triggers

In our analysis, we have focused on searching for miRNAs directly regulating genes causing TREDs by exploiting three commonly used algorithms (TargetScan, PicTar and DIANA-microT) for the target prediction. We combined the results obtained by these algorithms and showed graphically the distribution of putative miRNA binding sites in 3’UTRs (Fig. 4). The detailed list of all identified miRNAs and interaction parameters is presented as supplementary data.

Fig. (4). The graphical presentation of miRNA target sites distribution in 3’UTRs of TREDs genes predicted by selected algorithms.

Fig. (4). The graphical presentation of miRNA target sites distribution in 3’UTRs of TREDs genes predicted by selected algorithms.

The following algorithms were used for miRNA target prediction: TargetScanHuman Release 5.1 (only conserved sites for miRNA families broadly conserved among vertebrates were considered) (T), PicTar (Lall et al. 2006) (P) and DIANA-microT version 3.0 (D). A vertical bar depicts a single seed region of a miRNA target site predicted by the particular algorithm; putative target sites are marked by black vertical bars, experimentally validated by green rectangular-headed and false positives (experimentally rejected as untrue) by red star-headed bars. The absence of bars indicates that the algorithm did not predict any miRNAs targeting specified transcript or the transcript was not included in the UTR base used by this algorithm. The horizontal black lines with the division are scales with base pairs as a unit of measure. 3’UTRs of TREDs genes are grouped on the basis of their length. The sequence of 3’UTR that is common for all three algorithms is colored in pink. In the case of ATXN3 and CNBP 3’UTRs, the blue color indicates regions not analyzed by PicTar due to different criteria used to define 3’ UTR boundaries. No target sites were found for ATN1 and FXN genes. 3’UTR of ATXN8(OS) gene is not identified. The images of 3’UTRs with miRNA distribution were created using FancyGene v 1.4 [128].

Since both the number of miRNA sites and their arrangement influence the degree and specificity of miRNA-mediated gene repression [28] it is of utmost importance to carefully analyze the distribution of miRNA binding sites throughout the whole 3’UTR. Close attention should be paid to the following: the 3’UTR length, density of miRNA binding sites, existence of multiple sites and the distance between them (see the paragraph “miRNA-mRNA interactions”). We mapped miRNA recognition sites for 16 genes involved in the pathogenesis of TREDs and the outcomes of three algorithms were shown collectively one below the other as a triplicate-like analysis. Such a graphical presentation facilitates swift and correct interpretation of the results and therefore may help to choose miRNA-mRNA interactions for experimental validation. Additionally, we presented experimentally verified target sites found in the case of ATXN1 and FMR1 3’UTRs; the sites which were confirmed to be true are marked by green and rejected as untrue by red color. The analyzed TREDs-related genes varied significantly in their 3’UTR lengths, ranging from 436 nt in the case of AR gene to 9330 nt for AFF2 gene. 3’UTR lengths did not correlate with the number of miRNA binding sites. The HTT gene was predicted to have only a few sites for miRNA-mRNA interactions despite its significant length (3900 nt) while an abundance of putative miRNA sites was found for a relatively short (596 nt) ATXN2 gene. There were 7 and 19 binding sites in HTT and ATXN2 3’UTRs, respectively. Moreover, neither the number of miRNA sites nor their location in 3’UTR was readily comparable between results obtained by three algorithms. Although we chose programs that are based on sequence conservation alignment, their outcomes overlapped only to a limited extent. It is justifiable and seems to be a consequence of putting emphasis on different parameters for final scoring.

Our target prediction analysis served as a point of reference to discuss the recent achievements in the field of searching for links between miRNA and TREDs. Lee et al. [111] exploited PicTar for target prediction analysis of ATXN1 gene and showed its downregulation by three miRNAs while two out of three having multiple biding sites within 3’UTR of ATXN1 mRNA. Eight predicted miRNAs were chosen for the experimental analysis while PicTar predicts a lot more miRNAs being likely to associate with 3’UTR of ATXN1 (Fig. 4). PicTar indicated binding sites which are equally distributed within 3’UTR whereas TargetScan and DIANA-microT predicted fewer binding sites but they coincided to a high degree. Interestingly, all experimentally confirmed target sites were detected by each used algorithm which proved that approaches used by algorithm designers seem to be similarly efficient. One target site which turned out to be a false negative was detected only by PicTar, the second one both by DIANA-microT and PicTar while the third one by all algorithms. Although the minority of putative target sites were selected for validation, Lee et al. analyzed them thoroughly. miRNAs of chosen target sites were examined by miRNA duplex transfection and by the use of specific 2’-O-methyl inhibitors followed by measurement of the level of protein (western blot) and RNA decrease (RT-PCR). Exact validation of chosen target sites was carried out by using whole or parts of ATXN1 3’UTR fused with firefly luciferase reporter genes and by mutagenesis of putative sites. Furthermore, the coexpression of ATXN1 and specific miRNAs were shown by conducting a northern blot analysis and RNA in-situ hybridization. Such complete analysis meets the criteria elaborated by Kuhn et al. [95] to validated target sites as confirmed. Sinha et al. [115] demonstrated that gene encoding TATA-binding protein (TBP), which is mutated in SCA type 17 (SCA17), is downregulated by miR-146a. It was predicted by miRanda and RNAHybrid but none of the three algorithms used in our analysis managed to predict this interaction. This is another proof that miRNA target prediction still needs further modification and it is highly likely that all true miRNA interactions may not be predicted by using only one, two or even three algorithms. Recently, it has been demonstrated that three miRNAs interact with binding sites in the 3’UTR of FMR1 mRNA [116]. Yi et al. created constructs expressing a firefly luciferase with native FMR1 3’UTR and 3’UTR with mutated putative target sites and constructs of pre-miRNAs fused with green fluorescent protein (GFP). More extensive research has to be conducted to examine the impact of miRNAs downregulating the 3’UTR of FMR1 on its transcript and protein levels. The first of the positively validated sites were predicted both by PicTar and DIANA, the second one only by DIANA-microT and the third one exclusively by PicTar. The first site was also indicated by TargetScan with the annotation that this site is conservative but the potential miRNA belongs to the non-conservative family among mammals. Moreover, one of the rejected target site as untrue were not detected by neither of three target prediction programs. Other TREDs genes were not investigated for their direct regulation by miRNAs. Our computational analysis clearly shows that some of them, most of all AFF2 and ATXN2, may have multiple functional binding sites for miRNAs (Fig. 4) which are worthy for further examination and experimental validation. On the other hand, TBP has a short 3’UTR with only a few possible binding sites which is consistent with the results of the comprehensive analysis of the length and sequence of 3’UTRs of different genes. Taken together, this analysis showed that among TREDs’ triggers there are genes that are tightly regulated by miRNAs and genes involved in basic functions such as housekeeping genes, avoiding miRNA sites which observation has an evolutional explanation [117].

Studies of miRNA Deregulation in TREDs

Another approach to exploit miRNA regulation in TREDs studies for a better understanding the mechanism of neurodegeneration and a possible future clinical application was to compare miRNA expression levels between non-affected and affected individuals. Studies of D. melanogaster showed miRNAs are involved in modulation of neuron survival in response to the degeneration caused by polyglutaminate (polyQ) tracts [118, 119]. Ban, a fruit fly miRNA involved in tissue growth and programmed cell death [120], plays a protective role in polyQ-induced degeneration. Although there is no orthologue of ban in human cells, this regulation suggests that miRNAs can participate in TREDs pathogenesis by regulating cell degeneration or by being affected by mutant proteins or transcripts. Furthermore, many links between miRNA pathways and FMR1, the gene mutated in fragile X syndrome (FXS), were discovered [121, 122]. FMRP, the protein product of FMR1 gene, was proved to interact with key RISC proteins such as AGO1, AGO2 and Dicer and associate with endogenous miRNAs [123, 124]. Moreover, FMRP plays role in processing of pre-miRNAs [125, 126]. Several studies [92-94] proved that mutant huntingtin, a product of the HTT gene, is incapable of associating with Repressor element 1-silencing transcription factor (REST) which leads to repression of neural miRNAs and their lower levels in the brains of HD patients. Recent publications show miRNA deregulation in HD may be more extensive [86]. Marti et al. [127] used next generation sequencing (NGS) methods to identify the changes of miRNAs composition and their expression levels in patient with HD with reference to non-affected individuals. Moreover, significant changes in miRNA editing have been observed. Prediction and validation of genes targeted by miRNAs that are altered in HD patients is important for better understanding of pathogenic mechanisms leading to neurons death.

CONCLUDING REMARKS

Many computational tools have been designed for miRNA target prediction but may frequently lead to growing confusion. There is no single algorithm that can be used routinely for every analysis of 3’UTR sequences. Gaining more and more knowledge about miRNAs and their role in gene regulation prompted researchers to revise the way of analyzing individual miRNA-mRNA interactions. It is recommended to see miRNA regulation as a complex network involving genes targeted by many miRNAs and often having multiple sites for the same miRNA [94]. The outcome of such interactions is context-dependent and therefore it is difficult to reconstruct reliable miRNA-mRNA interactions in experiments conducted in vitro. Moreover, it is hard to assess to which extent the transcript level should be repressed to consider miRNA-mRNA interaction is truly functional.

On the strength of our current knowledge of miRNA-mRNA interactions we propose to follow a few guidelines for miRNA target prediction (Fig. 1). They originate in research studies considered in this paper and our discussions. We advise to use first miRNA target prediction algorithms focusing on the orthologous sequence alignment and then possibly apply algorithms considering other parameters such as free energy of binding or target site accessibility. The inverse correlation between expression levels of putative miRNA and targeted mRNA and/or protein levels increases the likelihood that this interaction is real and functional. Expression data can be obtained from microarray or proteomics databases or with the use of miRGator [66]. We would like to draw attention to the possibility of mutual interactions between miRNA sites located close to each other. We hope these conclusions will be beneficial for researches from other fields of biomedical sciences willing to implement the search for miRNAs in their molecular studies.

SUPPLEMENTARY MATERIAL

Supplementary material is available on the publishers Web site along with the published article.

CMM-11-93_SD1.zip (42.1KB, zip)

ACKNOWLEDGEMENTS

We would like to thank Jacek Witkos for reading the manuscript and for his critical suggestions.

This work was supported by the Ministry of Science and Higher Education (N N301 523038) and by the European Regional Development Fund within the Innovative Economy Programme (POIG.01.03.01-30-098/08).

REFERENCES

  • 1.Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19(1):92–105. doi: 10.1101/gr.082701.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010;11(9):597–610. doi: 10.1038/nrg2843. [DOI] [PubMed] [Google Scholar]
  • 3.Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: tools for microRNA genomics. Nucleic Acids Res. 2008;36(Database issue):D154–8. doi: 10.1093/nar/gkm952. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Chekulaeva M, Filipowicz W. Mechanisms of miRNA-mediated post-transcriptional regulation in animal cells. Curr Opin Cell Biol. 2009;21(3):452–60. doi: 10.1016/j.ceb.2009.04.009. [DOI] [PubMed] [Google Scholar]
  • 5.Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 2010;466(7308):835–40. doi: 10.1038/nature09267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ. Processing of primary microRNAs by the Microprocessor complex. Nature. 2004;432(7014):231–5. doi: 10.1038/nature03049. [DOI] [PubMed] [Google Scholar]
  • 7.Gregory RI, Yan KP, Amuthan G, et al. The Microprocessor complex mediates the genesis of microRNAs. Nature. 2004;432(7014):235–40. doi: 10.1038/nature03120. [DOI] [PubMed] [Google Scholar]
  • 8.Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature. 2001;409(6818):363–6. doi: 10.1038/35053110. [DOI] [PubMed] [Google Scholar]
  • 9.Hutvagner G, McLachlan J, Pasquinelli AE, et al. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science. 2001;293(5531):834–8. doi: 10.1126/science.1062961. [DOI] [PubMed] [Google Scholar]
  • 10.Hutvagner G, Zamore PD. A microRNA in a multiple-turnover RNAi enzyme complex. Science. 2002;297(5589):2056–60. doi: 10.1126/science.1073827. [DOI] [PubMed] [Google Scholar]
  • 11.Mourelatos Z, Dostie J, Paushkin S, et al. miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs. Genes Dev. 2002;16(6):720–8. doi: 10.1101/gad.974702. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Friedman JM, Jones PA. MicroRNAs: critical mediators of differentiation, development and disease. Swiss Med Wkly. 2009;139(33-34):466–72. doi: 10.4414/smw.2009.12794. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Gomase VS, Parundekar AN. microRNA: human disease and development. Int J Bioinform Res Appl. 2009;5(5):479–500. doi: 10.1504/IJBRA.2009.028678. [DOI] [PubMed] [Google Scholar]
  • 14.Melo SA, Esteller M. Dysregulation of microRNAs in cancer: Playing with fire. FEBS Lett. 2010 doi: 10.1016/j.febslet.2010.08.009. [DOI] [PubMed] [Google Scholar]
  • 15.Guller I, Russell AP. MicroRNAs in skeletal muscle: their role and regulation in development, disease and function. J Physiol. 2010;588(Pt 21):4075–87. doi: 10.1113/jphysiol.2010.194175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Hebert SS, De Strooper B. Alterations of the microRNA network cause neurodegenerative disease. Trends Neurosci. 2009;32(4):199–206. doi: 10.1016/j.tins.2008.12.003. [DOI] [PubMed] [Google Scholar]
  • 17.Jiang Q, Wang Y, Hao Y, et al. miR2Disease: a manually curated database for microRNA deregulation in human disease. Nucleic Acids Res. 2009;37(Database issue):D98–104. doi: 10.1093/nar/gkn714. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Ferracin M, Veronese A, Negrini M. Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev Mol Diagn. 2010;10(3):297–308. doi: 10.1586/erm.10.11. [DOI] [PubMed] [Google Scholar]
  • 19.Port JD, Sucharov C. Role of microRNAs in Cardiovascular Disease: Therapeutic Challenges and Potentials. J Cardiovasc Pharmacol. 2010;56(5):444–53. doi: 10.1097/FJC.0b013e3181f605b6. [DOI] [PubMed] [Google Scholar]
  • 20.Rossbach M. Small non-coding RNAs as novel therapeutics. Curr Mol Med. 2010;10(4):361–8. doi: 10.2174/156652410791317048. [DOI] [PubMed] [Google Scholar]
  • 21.Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–33. doi: 10.1016/j.cell.2009.01.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Voinnet O. Origin, biogenesis, and activity of plant microRNAs. Cell. 2009;136(4):669–87. doi: 10.1016/j.cell.2009.01.046. [DOI] [PubMed] [Google Scholar]
  • 23.Rhoades MW, Reinhart BJ, Lim LP, et al. Prediction of plant microRNA targets. Cell. 2002;110(4):513–20. doi: 10.1016/s0092-8674(02)00863-2. [DOI] [PubMed] [Google Scholar]
  • 24.Yekta S, Shih IH, Bartel DP. MicroRNA-directed cleavage of HOXB8 mRNA. Science. 2004;304(5670):594–6. doi: 10.1126/science.1097434. [DOI] [PubMed] [Google Scholar]
  • 25.Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5' UTR as in the 3' UTR. Proc Natl Acad Sci USA. 2007;104(23):9667–72. doi: 10.1073/pnas.0703820104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Tay Y, Zhang J, Thomson AM, Lim B, Rigoutsos I. MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature. 2008;455(7216):1124–8. doi: 10.1038/nature07299. [DOI] [PubMed] [Google Scholar]
  • 27.Forman JJ, Legesse-Miller A, Coller HA. A search for conserved sequences in coding regions reveals that the let-7 microRNA targets Dicer within its coding sequence. Proc Natl Acad Sci USA. 2008;105(39):14879–84. doi: 10.1073/pnas.0803230105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Hon LS, Zhang Z. The roles of binding site arrangement and combinatorial targeting in microRNA repression of gene expression. Genome Biol. 2007;8(8):R166. doi: 10.1186/gb-2007-8-8-r166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Gaidatzis D, van Nimwegen E, Hausser J, Zavolan M. Inference of miRNA targets using evolutionary conservation and pathway analysis. BMC Bioinformatics. 2007;8:69. doi: 10.1186/1471-2105-8-69. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Majoros WH, Ohler U. Spatial preferences of microRNA targets in 3' untranslated regions. BMC Genomics. 2007;8:152. doi: 10.1186/1471-2164-8-152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Lai EC. Predicting and validating microRNA targets. Genome Biol. 2004;5(9):115. doi: 10.1186/gb-2004-5-9-115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Brennecke J, Stark A, Russell RB, Cohen SM. Principles of microRNA-target recognition. PLoS Biol. 2005;3(3):e85. doi: 10.1371/journal.pbio.0030085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Grimson A, Farh KK, Johnston WK, et al. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell. 2007;27(1):91–105. doi: 10.1016/j.molcel.2007.06.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Doench JG, Petersen CP, Sharp PA. siRNAs can function as miRNAs. Genes Dev. 2003;17(4):438–42. doi: 10.1101/gad.1064703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Saetrom P, Heale BS, Snove O, Jr, et al. Distance constraints between microRNA target sites dictate efficacy and cooperativity. Nucleic Acids Res. 2007;35(7):2333–42. doi: 10.1093/nar/gkm133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Kiriakidou M, Nelson PT, Kouranov A, et al. A combined computational-experimental approach predicts human microRNA targets. Genes Dev. 2004;18(10):1165–78. doi: 10.1101/gad.1184704. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Lim LP, Lau NC, Weinstein EG, et al. The microRNAs of Caenorhabditis elegans. Genes Dev. 2003;17(8):991–1008. doi: 10.1101/gad.1074403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15–20. doi: 10.1016/j.cell.2004.12.035. [DOI] [PubMed] [Google Scholar]
  • 39.Nielsen CB, Shomron N, Sandberg R, et al. Determinants of targeting by endogenous and exogenous microRNAs and siRNAs. Rna. 2007;13(11):1894–910. doi: 10.1261/rna.768207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell. 2003;115(7):787–98. doi: 10.1016/s0092-8674(03)01018-3. [DOI] [PubMed] [Google Scholar]
  • 41.Chan CS, Elemento O, Tavazoie S. Revealing posttranscriptional regulatory elements through network-level conservation. PLoS Comput Biol. 2005;1(7):e69. doi: 10.1371/journal.pcbi.0010069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Krek A, Grun D, Poy MN, et al. Combinatorial microRNA target predictions. Nat Genet. 2005;37(5):495–500. doi: 10.1038/ng1536. [DOI] [PubMed] [Google Scholar]
  • 43.Didiano D, Hobert O. Perfect seed pairing is not a generally reliable predictor for miRNA-target interactions. Nat Struct Mol Biol. 2006;13(9):849–51. doi: 10.1038/nsmb1138. [DOI] [PubMed] [Google Scholar]
  • 44.Bernhart SH, Tafer H, Muckstein U, et al. Partition function and base pairing probabilities of RNA heterodimers. Algorithms Mol Biol. 2006;1(1):3. doi: 10.1186/1748-7188-1-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Long D, Lee R, Williams P, et al. Potent effect of target structure on microRNA function. Nat Struct Mol Biol. 2007;14(4):287–94. doi: 10.1038/nsmb1226. [DOI] [PubMed] [Google Scholar]
  • 46.Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E. The role of site accessibility in microRNA target recognition. Nat Genet. 2007;39(10):1278–84. doi: 10.1038/ng2135. [DOI] [PubMed] [Google Scholar]
  • 47.Hobert O. miRNAs play a tune. Cell. 2007;131(1):22–4. doi: 10.1016/j.cell.2007.09.031. [DOI] [PubMed] [Google Scholar]
  • 48.Seitz H. Redefining microRNA targets. Curr Biol. 2009;19(10):870–3. doi: 10.1016/j.cub.2009.03.059. [DOI] [PubMed] [Google Scholar]
  • 49.Sethupathy P, Corda B, Hatzigeorgiou AG. TarBase: A comprehensive database of experimentally supported animal microRNA targets. Rna. 2006;12(2):192–7. doi: 10.1261/rna.2239606. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Papadopoulos GL, Reczko M, Simossis VA, Sethupathy P, Hatzigeorgiou AG. The database of experimentally supported targets: a functional update of TarBase. Nucleic Acids Res. 2009;37(Database issue):D155–8. doi: 10.1093/nar/gkn809. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Maziere P, Enright AJ. Prediction of microRNA targets. Drug Discov Today. 2007;12(11-12):452–8. doi: 10.1016/j.drudis.2007.04.002. [DOI] [PubMed] [Google Scholar]
  • 52.Min H, Yoon S. Got target? Computational methods for microRNA target prediction and their extension. Exp Mol Med. 2010;42(4):233–44. doi: 10.3858/emm.2010.42.4.032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Saito T, Saetrom P. MicroRNAs--targeting and target prediction. N Biotechnol. 2010;27(3):243–9. doi: 10.1016/j.nbt.2010.02.016. [DOI] [PubMed] [Google Scholar]
  • 54.Thomas M, Lieberman J, Lal A. Desperately seeking microRNA targets. Nat Struct Mol Biol. 2010;17(10):1169–74. doi: 10.1038/nsmb.1921. [DOI] [PubMed] [Google Scholar]
  • 55.Yue D, Liu H, Huang Y. Survey of Computational Algorithms for MicroRNA Target Prediction. Curr Genomics. 2009;10(7):478–92. doi: 10.2174/138920209789208219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.John B, Enright AJ, Aravin A, et al. Human MicroRNA targets. PLoS Biol. 2004;2(11):e363. doi: 10.1371/journal.pbio.0020363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Lall S, Grun D, Krek A, et al. A genome-wide map of conserved microRNA targets in C. elegans. Curr Biol. 2006;16(5):460–71. doi: 10.1016/j.cub.2006.01.050. [DOI] [PubMed] [Google Scholar]
  • 58.Miranda KC, Huynh T, Tay Y, et al. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell. 2006;126(6):1203–17. doi: 10.1016/j.cell.2006.07.031. [DOI] [PubMed] [Google Scholar]
  • 59.Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA.org resource: targets and expression. Nucleic Acids Res. 2008;36(Database issue):D149–53. doi: 10.1093/nar/gkm995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Maragkakis M, Alexiou P, Papadopoulos GL, et al. Accurate microRNA target prediction correlates with protein repression levels. BMC Bioinformatics. 2009;10:295. doi: 10.1186/1471-2105-10-295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Sethupathy P, Megraw M, Hatzigeorgiou AG. A guide through present computational approaches for the identification of mammalian microRNA targets. Nat Methods. 2006;3(11):881–6. doi: 10.1038/nmeth954. [DOI] [PubMed] [Google Scholar]
  • 62.Baek D, Villen J, Shin C, et al. The impact of microRNAs on protein output. Nature. 2008;455(7209):64–71. doi: 10.1038/nature07242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Alexiou P, Maragkakis M, Papadopoulos GL, Reczko M, Hatzigeorgiou AG. Lost in translation: an assessment and perspective for computational microRNA target identification. Bioinformatics. 2009;25(23):3049–55. doi: 10.1093/bioinformatics/btp565. [DOI] [PubMed] [Google Scholar]
  • 64.Selbach M, Schwanhausser B, Thierfelder N, et al. Widespread changes in protein synthesis induced by microRNAs. Nature. 2008;455(7209):58–63. doi: 10.1038/nature07228. [DOI] [PubMed] [Google Scholar]
  • 65.Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005;433(7027):769–73. doi: 10.1038/nature03315. [DOI] [PubMed] [Google Scholar]
  • 66.Cho S, Jun Y, Lee S, et al. miRGator v2.0 : an integrated system for functional investigation of microRNAs. Nucleic Acids Res. 2010 doi: 10.1093/nar/gkq1094. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Esau C, Davis S, Murray SF, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006;3(2):87–98. doi: 10.1016/j.cmet.2006.01.005. [DOI] [PubMed] [Google Scholar]
  • 68.Liu Z, Sall A, Yang D. MicroRNA: An emerging therapeutic target and intervention tool. Int J Mol Sci. 2008;9(6):978–99. doi: 10.3390/ijms9060978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Olejniczak M, Galka P, Krzyzosiak WJ. Sequence-non-specific effects of RNA interference triggers and microRNA regulators. Nucleic Acids Res. 38(1):1–16. doi: 10.1093/nar/gkp829. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Davis S, Lollo B, Freier S, Esau C. Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res. 2006;34(8):2294–304. doi: 10.1093/nar/gkl183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Orom UA, Kauppinen S, Lund AH. LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene. 2006;372:137–41. doi: 10.1016/j.gene.2005.12.031. [DOI] [PubMed] [Google Scholar]
  • 72.Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature. 2005;438(7068):685–9. doi: 10.1038/nature04303. [DOI] [PubMed] [Google Scholar]
  • 73.Cohen SM. Use of microRNA sponges to explore tissue-specific microRNA functions in vivo. Nat Methods. 2009;6(12):873–4. doi: 10.1038/nmeth1209-873. [DOI] [PubMed] [Google Scholar]
  • 74.Ebert MS, Sharp PA. Emerging roles for natural microRNA sponges. Curr Biol. 2010;20(19):R858–61. doi: 10.1016/j.cub.2010.08.052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Xiao F, Zuo Z, Cai G, et al. miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res. 2009;37(Database issue):D105–10. doi: 10.1093/nar/gkn851. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Shahi P, Loukianiouk S, Bohne-Lang A, et al. Argonaute--a database for gene regulation by mammalian microRNAs. Nucleic Acids Res. 2006;34(Database issue):D115–8. doi: 10.1093/nar/gkj093. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Hsu SD, Chu CH, Tsou AP, et al. miRNAMap 2.0: genomic maps of microRNAs in metazoan genomes. Nucleic Acids Res. 2008;36(Database issue):D165–9. doi: 10.1093/nar/gkm1012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Felli N, Fontana L, Pelosi E, et al. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci USA. 2005;102(50):18081–6. doi: 10.1073/pnas.0506216102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell. 2005;120(5):635–47. doi: 10.1016/j.cell.2005.01.014. [DOI] [PubMed] [Google Scholar]
  • 80.Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA. 2005;102(39):13944–9. doi: 10.1073/pnas.0506654102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature. 2005;435(7043):839–43. doi: 10.1038/nature03677. [DOI] [PubMed] [Google Scholar]
  • 82.Koscianska E, Baev V, Skreka K, et al. Prediction and preliminary validation of oncogene regulation by miRNAs. BMC Mol Biol. 2007;8:79. doi: 10.1186/1471-2199-8-79. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Wu S, Huang S, Ding J, et al. Multiple microRNAs modulate p21Cip1/Waf1 expression by directly targeting its 3' untranslated region. Oncogene. 2010;29(15):2302–8. doi: 10.1038/onc.2010.34. [DOI] [PubMed] [Google Scholar]
  • 84.Wang X, Wang X. Systematic identification of microRNA functions by combining target prediction and expression profiling. Nucleic Acids Res. 2006;34(5):1646–52. doi: 10.1093/nar/gkl068. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Ziegelbauer JM, Sullivan CS, Ganem D. Tandem array-based expression screens identify host mRNA targets of virus-encoded microRNAs. Nat Genet. 2009;41(1):130–4. doi: 10.1038/ng.266. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Vinther J, Hedegaard MM, Gardner PP, Andersen JS, Arctander P. Identification of miRNA targets with stable isotope labeling by amino acids in cell culture. Nucleic Acids Res. 2006;34(16):e107. doi: 10.1093/nar/gkl590. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Jin H, Tuo W, Lian H, et al. Strategies to identify microRNA targets: New advances. N Biotechnol. 2010;27(6):734–8. doi: 10.1016/j.nbt.2010.09.006. [DOI] [PubMed] [Google Scholar]
  • 88.Beitzinger M, Peters L, Zhu JY, Kremmer E, Meister G. Identification of human microRNA targets from isolated argonaute protein complexes. RNA Biol. 2007;4(2):76–84. doi: 10.4161/rna.4.2.4640. [DOI] [PubMed] [Google Scholar]
  • 89.Easow G, Teleman AA, Cohen SM. Isolation of microRNA targets by miRNP immunopurification. RNA. 2007;13(8):1198–204. doi: 10.1261/rna.563707. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Chi SW, Zang JB, Mele A, Darnell RB. Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature. 2009;460(7254):479–86. doi: 10.1038/nature08170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91.Hafner M, Landthaler M, Burger L, et al. PAR-CliP--a method to identify transcriptome-wide the binding sites of RNA binding proteins. J Vis Exp. 2010;pii(41):2034. doi: 10.3791/2034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92.Davis E, Caiment F, Tordoir X, et al. RNAi-mediated allelic trans-interaction at the imprinted Rtl1/Peg11 locus. Curr Biol. 2005;15(8):743–9. doi: 10.1016/j.cub.2005.02.060. [DOI] [PubMed] [Google Scholar]
  • 93.Li J, Xia W, Huang B, et al. A strategy to rapidly identify the functional targets of microRNAs by combining bioinformatics and mRNA cytoplasmic/nucleic ratios in culture cells. FEBS Lett. 2010;584(14):3198–202. doi: 10.1016/j.febslet.2010.06.012. [DOI] [PubMed] [Google Scholar]
  • 94.Peter ME. Targeting of mRNAs by multiple miRNAs: the next step. Oncogene. 2010;29(15):2161–4. doi: 10.1038/onc.2010.59. [DOI] [PubMed] [Google Scholar]
  • 95.Kuhn DE, Martin MM, Feldman DS, et al. Experimental validation of miRNA targets. Methods. 2008;44(1):47–54. doi: 10.1016/j.ymeth.2007.09.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96.Nelson PT, Kiriakidou M, Mourelatos Z, et al. High-throughput experimental studies to identify miRNA targets directly, with special focus on the mammalian brain. Brain Res. 2010;1338:122–30. doi: 10.1016/j.brainres.2010.03.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97.Krichevsky AM, King KS, Donahue CP, Khrapko K, Kosik KS. A microRNA array reveals extensive regulation of microRNAs during brain development. RNA. 2003;9(10):1274–81. doi: 10.1261/rna.5980303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98.Kosik KS. MicroRNAs tell an evo-devo story. Nat Rev Neurosci. 2009;10(10):754–9. doi: 10.1038/nrn2713. [DOI] [PubMed] [Google Scholar]
  • 99.Christensen M, Schratt GM. microRNA involvement in developmental and functional aspects of the nervous system and in neurological diseases. Neurosci Lett. 2009;466(2):55–62. doi: 10.1016/j.neulet.2009.04.043. [DOI] [PubMed] [Google Scholar]
  • 100.Schratt G. Fine-tuning neural gene expression with microRNAs. Curr Opin Neurobiol. 2009;19(2):213–9. doi: 10.1016/j.conb.2009.05.015. [DOI] [PubMed] [Google Scholar]
  • 101.Barbato C, Ruberti F, Cogoni C. Searching for MIND: microRNAs in neurodegenerative diseases. J Biomed Biotechnol. 2009;2009:871313. doi: 10.1155/2009/871313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 102.Martino S, di Girolamo I, Orlacchio A, Datti A, Orlacchio A. MicroRNA implications across neurodevelopment and neuropathology. J Biomed Biotechnol. 2009;2009:654346. doi: 10.1155/2009/654346. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103.Roshan R, Ghosh T, Scaria V, Pillai B. MicroRNAs: novel therapeutic targets in neurodegenerative diseases. Drug Discov Today. 2009;14(23-24):1123–9. doi: 10.1016/j.drudis.2009.09.009. [DOI] [PubMed] [Google Scholar]
  • 104.Lau P, de Strooper B. Dysregulated microRNAs in neurodegenerative disorders. Semin Cell Dev Biol. 2010;21(7):768–73. doi: 10.1016/j.semcdb.2010.01.009. [DOI] [PubMed] [Google Scholar]
  • 105.Schaefer A, O'Carroll D, Tan CL, et al. Cerebellar neurodegeneration in the absence of microRNAs. J Exp Med. 2007;204(7):1553–8. doi: 10.1084/jem.20070823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106.Orr HT, Zoghbi HY. Trinucleotide repeat disorders. Annu Rev Neurosci. 2007;30:575–621. doi: 10.1146/annurev.neuro.29.051605.113042. [DOI] [PubMed] [Google Scholar]
  • 107.Mirkin SM. Expandable DNA repeats and human disease. Nature. 2007;447(7147):932–40. doi: 10.1038/nature05977. [DOI] [PubMed] [Google Scholar]
  • 108.Lopez Castel A, Cleary JD, Pearson CE. Repeat instability as the basis for human diseases and as a potential target for therapy. Nat Rev Mol Cell Biol. 2010;11(3):165–70. doi: 10.1038/nrm2854. [DOI] [PubMed] [Google Scholar]
  • 109.Birman S. Neurodegeneration: RNA turns number one suspect in polyglutamine diseases. Curr Biol. 2008;18(15):R659–61. doi: 10.1016/j.cub.2008.06.023. [DOI] [PubMed] [Google Scholar]
  • 110.Li LB, Bonini NM. Roles of trinucleotide-repeat RNA in neurological disease and degeneration. Trends Neurosci. 2010;33(6):292–8. doi: 10.1016/j.tins.2010.03.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 111.Lee Y, Samaco RC, Gatchel JR, et al. miR-19, miR-101 and miR-130 co-regulate ATXN1 levels to potentially modulate SCA1 pathogenesis. Nat Neurosci. 2008;11(10):1137–9. doi: 10.1038/nn.2183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 112.Boudreau RL, McBride JL, Martins I, et al. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther. 2009;17(6):1053–63. doi: 10.1038/mt.2009.17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113.Ho TH, Savkur RS, Poulos MG, et al. Colocalization of muscleblind with RNA foci is separable from mis-regulation of alternative splicing in myotonic dystrophy. J Cell Sci. 2005;118(Pt 13):2923–33. doi: 10.1242/jcs.02404. [DOI] [PubMed] [Google Scholar]
  • 114.Hwang HW, Wentzel EA, Mendell JT. A hexanucleotide element directs microRNA nuclear import. Science. 2007;315(5808):97–100. doi: 10.1126/science.1136235. [DOI] [PubMed] [Google Scholar]
  • 115.Sinha M, Ghose J, Das E, Bhattarcharyya NP. Altered microRNAs in STHdh(Q111)/Hdh(Q111) cells: miR-146a targets TBP. Biochem Biophys Res Commun. 2010;396(3):742–7. doi: 10.1016/j.bbrc.2010.05.007. [DOI] [PubMed] [Google Scholar]
  • 116.Yi YH, Sun XS, Qin JM, et al. Experimental identification of microRNA targets on the 3' untranslated region of human FMR1 gene. J Neurosci Methods. 2010;190(1):34–8. doi: 10.1016/j.jneumeth.2010.04.022. [DOI] [PubMed] [Google Scholar]
  • 117.Stark A, Brennecke J, Bushati N, Russell RB, Cohen SM. Animal MicroRNAs confer robustness to gene expression and have a significant impact on 3'UTR evolution. Cell. 2005;123(6):1133–46. doi: 10.1016/j.cell.2005.11.023. [DOI] [PubMed] [Google Scholar]
  • 118.Bilen J, Liu N, Bonini NM. A new role for microRNA pathways: modulation of degeneration induced by pathogenic human disease proteins. Cell Cycle. 2006;5(24):2835–8. doi: 10.4161/cc.5.24.3579. [DOI] [PubMed] [Google Scholar]
  • 119.Bilen J, Liu N, Burnett BG, Pittman RN, Bonini NM. MicroRNA pathways modulate polyglutamine-induced neurodegeneration. Mol Cell. 2006;24(1):157–63. doi: 10.1016/j.molcel.2006.07.030. [DOI] [PubMed] [Google Scholar]
  • 120.Brennecke J, Hipfner DR, Stark A, Russell RB, Cohen SM. bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell. 2003;113(1):25–36. doi: 10.1016/s0092-8674(03)00231-9. [DOI] [PubMed] [Google Scholar]
  • 121.Jin P, Alisch RS, Warren ST. RNA and microRNAs in fragile X mental retardation. Nat Cell Biol. 2004;6(11):1048–53. doi: 10.1038/ncb1104-1048. [DOI] [PubMed] [Google Scholar]
  • 122.Cheever A, Ceman S. Translation regulation of mRNAs by the fragile X family of proteins through the microRNA pathway. RNA Biol. 2009;6(2):175–8. doi: 10.4161/rna.6.2.8196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 123.Caudy AA, Myers M, Hannon GJ, Hammond SM. Fragile X-related protein and VIG associate with the RNA interference machinery. Genes Dev. 2002;16(19):2491–6. doi: 10.1101/gad.1025202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 124.Yang L, Duan R, Chen D, et al. Fragile X mental retardation protein modulates the fate of germline stem cells in Drosophila. Hum Mol Genet. 2007;16(15):1814–20. doi: 10.1093/hmg/ddm129. [DOI] [PubMed] [Google Scholar]
  • 125.Xu XL, Li Y, Wang F, Gao FB. The steady-state level of the nervous-system-specific microRNA-124a is regulated by dFMR1 in Drosophila. J Neurosci. 2008;28(46):11883–9. doi: 10.1523/JNEUROSCI.4114-08.2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 126.Cheever A, Ceman S. Phosphorylation of FMRP inhibits association with Dicer. RNA. 2009;15(3):362–6. doi: 10.1261/rna.1500809. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 127.Marti E, Pantano L, Banez-Coronel M, et al. A myriad of miRNA variants in control and Huntington's disease brain regions detected by massively parallel sequencing. Nucleic Acids Res. 2010;38(20):7219–35. doi: 10.1093/nar/gkq575. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 128.Rambaldi D, Ciccarelli FD. FancyGene: dynamic visualization of gene structures and protein domain architectures on genomic loci. Bioinformatics. 2009;25(17):2281–2. doi: 10.1093/bioinformatics/btp381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 129.Karres JS, Hilgers V, Carrera I, Treisman J, Cohen SM. The conserved microRNA miR-8 tunes atrophin levels to prevent neurodegeneration in Drosophila. Cell. 2007;131(1):136–45. doi: 10.1016/j.cell.2007.09.020. [DOI] [PubMed] [Google Scholar]
  • 130.Packer AN, Xing Y, Harper SQ, Jones L, Davidson BL. The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington's disease. J Neurosci. 2008;28(53):14341–6. doi: 10.1523/JNEUROSCI.2390-08.2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 131.Johnson R, Zuccato C, Belyaev ND, et al. A microRNA-based gene dysregulation pathway in Huntington's disease. Neurobiol Dis. 2008;29(3):438–45. doi: 10.1016/j.nbd.2007.11.001. [DOI] [PubMed] [Google Scholar]
  • 132.Johnson R, Buckley NJ. Gene dysregulation in Huntington's disease: REST, microRNAs and beyond. Neuromol Med. 2009;11(3):183–99. doi: 10.1007/s12017-009-8063-4. [DOI] [PubMed] [Google Scholar]
  • 133.Batuwita R, Palade V. microPred: effective classification of pre-miRNAs for human miRNA gene prediction. Bioinformatics. 2009;25(8):989–95. doi: 10.1093/bioinformatics/btp107. [DOI] [PubMed] [Google Scholar]
  • 134.Gambardella S, Rinaldi F, Lepore SM, et al. Overexpression of microRNA-206 in the skeletal muscle from myotonic dystrophy type 1 patients. J Transl Med. 2010;8:48. doi: 10.1186/1479-5876-8-48. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary material is available on the publishers Web site along with the published article.

CMM-11-93_SD1.zip (42.1KB, zip)

Articles from Current Molecular Medicine are provided here courtesy of Bentham Science Publishers

RESOURCES